How to buy AVROBIO stock (AVRO)

AVROBIO is a biotechnology business based in the US. AVROBIO shares (AVRO) are listed on the NASDAQ and all prices are listed in US Dollars. AVROBIO employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy AVROBIO stock

Buy AVROBIO stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AVROBIO stock price (NASDAQ: AVRO)

Use our graph to track the performance of AVRO stocks over time.

AVROBIO shares at a glance

• Key figures

Information last updated 2024-08-18.

52-week range	$0.00 - $0.00
50-day moving average more info button	$16.17
200-day moving average more info button	$16.46
Wall St. target price	$2.00
PE ratio more info button	0.1691
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$8.28

Is it a good time to buy AVROBIO stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is AVROBIO stock undervalued or overvalued?

Valuing AVROBIO stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AVROBIO's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AVROBIO's P/E ratio

AVROBIO's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, AVROBIO shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

AVROBIO financials

Gross profit TTM	$0
Return on assets TTM	-35.18%
Return on equity TTM	42.73%
Profit margin	0%
Book value	$23.75
Market Capitalization more info button	$5.2 million

TTM: trailing 12 months

AVROBIO share dividends

We're not expecting AVROBIO to pay a dividend over the next 12 months.

Have AVROBIO's shares ever split?

AVROBIO's shares were split on a 1:12 basis on 20 June 2024 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVROBIO shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for AVROBIO shares which in turn could have impacted AVROBIO's share price.

AVROBIO share price volatility

Over the last 12 months, AVROBIO's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVROBIO's is 1.223. This would suggest that AVROBIO's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

AVROBIO overview

AVROBIO, Inc. , a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

null
What percentage of AVROBIO is owned by insiders or institutions?
Currently 1.653% of AVROBIO shares are held by insiders and 68.802% by institutions. How many people work for AVROBIO?
Latest data suggests 13 work at AVROBIO. When does the fiscal year end for AVROBIO?
AVROBIO's fiscal year ends in December. Where is AVROBIO based?
AVROBIO's address is: 100 Technology Square, Cambridge, MA, United States, 02139 What is AVROBIO's ISIN number?
AVROBIO's international securities identification number is: US05455M1009 What is AVROBIO's CUSIP number?
AVROBIO's Committee on Uniform Securities Identification Procedures number is: 05455M100